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Summary 
Background 
Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple 
myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. 
The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib 
and dexamethasone in patients with relapsed or refractory multiple myeloma. 
Methods 
In this randomised, phase 3, open-label, multicentre study, patients with relapsed or refractory multiple 
myeloma who had one to three previous treatments were randomly assigned (1:1) using a blocked 
randomisation scheme (block size of four) to receive carfilzomib with dexamethasone (carfilzomib group) or 
bortezomib with dexamethasone (bortezomib group). Randomisation was stratified by previous 
proteasome inhibitor therapy, previous lines of treatment, International Staging System stage, and planned 
route of bortezomib administration if randomly assigned to bortezomib with dexamethasone. Patients 
received treatment until progression with carfilzomib (20 mg/m2 on days 1 and 2 of cycle 1; 56 mg/m2 
thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or 
bortezomib (1·3 mg/m2; intravenous bolus or subcutaneous injection) and dexamethasone (20 mg oral or 
intravenous infusion). The primary endpoint was progression-free survival in the intention-to-treat 
population. All participants who received at least one dose of study drug were included in the safety 
analyses. The study is ongoing but not enrolling participants; results for the interim analysis of the primary 
endpoint are presented. The trial is registered at ClinicalTrials.gov, number NCT01568866. 
Findings 
Between June 20, 2012, and June 30, 2014, 929 patients were randomly assigned (464 to the carfilzomib 
group; 465 to the bortezomib group). Median follow-up was 11·9 months (IQR 9·3–16·1) in the carfilzomib 
group and 11·1 months (8·2–14·3) in the bortezomib group. Median progression-free survival was 18·7 
months (95% CI 15·6–not estimable) in the carfilzomib group versus 9·4 months (8·4–10·4) in the 
bortezomib group at a preplanned interim analysis (hazard ratio [HR] 0·53 [95% CI 0·44–0·65]; p<0·0001). 
On-study death due to adverse events occurred in 18 (4%) of 464 patients in the carfilzomib group and in 
16 (3%) of 465 patients in the bortezomib group. Serious adverse events were reported in 224 (48%) of 463 
patients in the carfilzomib group and in 162 (36%) of 456 patients in the bortezomib group. The most 
frequent grade 3 or higher adverse events were anaemia (67 [14%] of 463 patients in the carfilzomib group 
vs 45 [10%] of 456 patients in the bortezomib group), hypertension (41 [9%] vs 12 [3%]), thrombocytopenia 
(39 [8%] vs 43 [9%]), and pneumonia (32 [7%] vs 36 [8%]). 
Interpretation 
For patients with relapsed or refractory multiple myeloma, carfilzomib with dexamethasone could be 
considered in cases in which bortezomib with dexamethasone is a potential treatment option. 
Funding 




Multiple myeloma is a common and often fatal haematological malignancy. New treatment options, such as 
the first-in-class proteasome inhibitor bortezomib, have prolonged survival in patients with this disease.1 
and 2 Bortezomib was first approved in 2003 in the USA for the treatment of multiple myeloma and is given 
with dexamethasone as a standard treatment for relapsed or refractory disease worldwide.3 and 4 
Importantly, bortezomib given twice weekly as an intravenous infusion is associated with high rates of 
peripheral neuropathy (all grades, 34–54%; grade 3 or higher, 8–16%).3, 4, 5 and 6 Furthermore, peripheral 
neuropathy is among the most common adverse events leading to treatment discontinuation (4–8% of 
patients) in phase 2 and 3 studies with bortezomib.3, 6 and 7 
When compared with intravenous administration, subcutaneous administration of bortezomib showed 
non-inferior efficacy (overall response in 42% of patients in both groups) and lower frequency grade 2 or 
higher (24% vs 39%) and grade 3 or higher peripheral neuropathy (6% vs 16%). 5 Additionally, a once-
weekly infusion of bortezomib in combination with melphalan and prednisone with or without thalidomide 
showed significantly reduced frequencies of grade 3–4 peripheral neuropathy compared with a twice-
weekly schedule (8% vs 28%) without a reduction in efficacy. 8 However, there are no published data from 
randomised trials that have compared the once-weekly schedule of bortezomib alone with the standard 
twice-weekly schedule, and the once-weekly schedule is not included in the bortezomib label. Although 
once-weekly and subcutaneous administration of bortezomib is associated with improved tolerability and 
convenience of this drug compared with twice-weekly administration, new anti-myeloma regimens are 
needed that are more effective and better tolerated. 
Carfilzomib is a selective proteasome inhibitor that is approved in the USA for use as a single agent in 
patients with relapsed and refractory multiple myeloma or in combination with lenalidomide and 
dexamethasone in patients with relapsed multiple myeloma (one to three previous lines of therapy), at 
doses of 20 mg/m2 (starting dose) and 27 mg/m2 (target dose) infused over 10 min. Carfilzomib irreversibly 
binds to the proteasome, which results in more sustained proteasomal inhibition than that produced by 
bortezomib. In a phase 1b/2 study,9 carfilzomib given at higher doses (20 mg/m2 [starting dose] and 56 
mg/m2 [target dose]) and for a longer infusion time (30 min) showed promising activity and tolerability in 
combination with dexamethasone in patients with relapsed or refractory multiple myeloma or both. We 
initiated this randomised, open-label, multicentre, phase 3 study (ENDEAVOR) to compare carfilzomib and 




Study design and participants 
In this randomised, open-label, phase 3 study patients were recruited from 198 sites in North America, 
Europe, South America, and the Asia-Pacific region (appendix pp 3–6). Patients aged 18 years or older with 
relapsed or refractory multiple myeloma, measurable disease (ie, serum M-protein of at least 5 g/L or urine 
M-protein of at least 200 mg/24 h; or in patients without detectable serum or urine M-protein, serum free 
light chain of at least 100 mg/L [involved light chain] and an abnormal serum κ:λ ratio), Eastern Cooperative 
Oncology Group performance status of 0 to 2, one to three previous treatments, and at least a partial 
response to at least one previous treatment were eligible. Previous treatments could include carfilzomib or 
bortezomib if patients achieved at least a partial response before relapse or progression, were not 
discontinued due to toxic effects, and had at least a 6 month proteasome inhibitor treatment-free interval 
before enrolment (patients could have received maintenance therapy with drugs that are not in the 
proteasome inhibitor class during this 6 month interval). Eligible patients were required to have an absolute 
neutrophil count of at least 1000 cells per μL and a platelet count of at least 50 000 cells per μL (≥30 000 
cells per μL if myeloma involvement in the bone marrow was >50%) within 21 days before randomisation; 
left ventricular ejection fraction of at least 40%; and creatinine clearance of at least 15 mL/min. Patients 
were excluded if they had grade 2 (with pain), grade 3, or grade 4 peripheral neuropathy within 14 days 
before randomisation, myocardial infarction within 4 months before randomisation, or New York Heart 
Association class III or IV heart failure. All patients provided written informed consent. The study protocol 
was approved by the institutional review boards or ethics committees of all participating institutions. 
 
Randomisation and masking 
Patients were randomly assigned (1:1) using an interactive voice and web response system to receive 
carfilzomib and dexamethasone (carfilzomib group) or bortezomib and dexamethasone (bortezomib 
group). Randomisation was stratified by previous proteasome inhibitor therapy (yes vs no), previous lines 
of treatment (one vs two or three), International Staging System stage (I vs II–III), and planned route of 
bortezomib administration (intravenous vs subcutaneous) if randomly assigned to the bortezomib group. 
Within each stratum, patients were randomly assigned using a block randomisation scheme (block size of 
four). Due to the different dosing schedules of the treatment regimens, the study was open label, and 
therefore the allocated treatment was not masked from study investigators or patients. Potential bias in 
the assessment of the primary endpoint was mitigated by using an independent review committee, masked 
to treatment allocation, for the determination of disease status. Furthermore, the funder remained masked 
to per-group treatment results during the study. The success of masking was not assessed. 
 
Procedures 
The carfilzomib group received carfilzomib (20 mg/m2 on days 1 and 2 of cycle 1; 56 mg/m2 given 
thereafter; 30 min intravenous infusion) on days 1, 2, 8, 9, 15, and 16 and dexamethasone (20 mg oral or 
intravenous infusion) on days 1, 2, 8, 9, 15, 16, 22, and 23 of a 28-day cycle. The rationale for using these 
doses rather than the approved doses of 20 mg/m2 and 27 mg/m2 was based on preliminary efficacy 
results from the 56 mg/m2 cohort of a phase 1b/2 study of carfilzomib in patients with relapsed or 
refractory multiple myeloma or both, in which a higher proportion of patients responded than that in a 
similar population from the pivotal phase 2 study of single-agent carfilzomib (27 mg/m2), but with a 
qualitatively comparable safety profile.9 and 10 Intravenous hydration (250–500 mL before and after dose 
administration) was given during cycle 1 and at the investigator's discretion thereafter. The bortezomib 
group received bortezomib (1·3 mg/m2; 3–5 s intravenous bolus or subcutaneous injection) on days 1, 4, 8, 
and 11, and dexamethasone (20 mg oral or intravenous infusion) on days 1, 2, 4, 5, 8, 9, 11, and 12 of a 21-
day cycle. Intravenous hydration was not required in the bortezomib group. The route of administration of 
bortezomib was chosen by the investigators in accordance with local regulatory approval. Relative dose 
intensity was calculated as the ratio of the actual dose intensity to the planned dose intensity that was 
based on the above-standard dosing level and schedule throughout the treatment period. Cycles were 
repeated until disease progression, withdrawal of consent, or unacceptable toxic effects. All patients 
received antiviral and proton pump inhibitor therapies. 
Dose reductions were permitted to manage toxic effects. Protocol-specific guidance for carfilzomib or 
bortezomib dose modifications was given for several adverse events (appendix pp 7–11). Conditions not 
requiring dose reductions included grade 3 nausea, vomiting, or diarrhoea (unless persisting more than 3 
days despite adequate treatment with antiemetics or antidiarrhoeal agents), grade 3 fatigue (unless 
persisting for more than 14 days), any grade anaemia or lymphopenia, and alopecia. 
Blood and urine samples to assess disease status were collected at baseline and every 4 weeks thereafter, 
and were analysed at a central laboratory using serum protein electrophoresis, urine protein 
electrophoresis, immunofixation, and measurement of serum-free light-chain concentrations and 
quantitative immunoglobulins. Disease response data were assessed in a masked manner by an 
independent review committee, and were used for the primary analyses of progression-free survival, 
overall response, and duration of response. Additional details regarding the independent review committee 
are given in the appendix (p 7). Response assessments were made using the International Myeloma 
Working Group—Uniform Response Criteria.11 and 12 After study treatment discontinuation, patients 
were followed for disease status every 4 weeks until progression (if not already progressed during 
treatment) and for survival every 3 months until study closure. 
Adverse event and laboratory data were collected until 30 days after last dose of study treatment. Adverse 
events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 4.03. 
Haematological laboratory assessments were done at a central laboratory at screening and on days 1, 8, 
and 15 (carfilzomib group) or days 1 and 8 (bortezomib group) of each treatment cycle. Full serum 
chemistries (appendix p 12) were measured at a central laboratory at screening and on day 1 of each 
treatment cycle. Abbreviated serum chemistries were done on days 8 and 15 (carfilzomib group) or day 8 
(bortezomib group) of each cycle. Abbreviated serum chemistries (appendix p 12) were also done on days 
2, 9, and 16 (carfilzomib group) or on days 4 and 11 (bortezomib group) of cycle 1. We assessed cytogenetic 
risk status using fluorescence in-situ hybridisation. Patients were defined as high risk if they had the genetic 
subtypes t(4;14) or t(14;16) in 10% or more of screened plasma cells, or deletion 17p in 20% or more of 
screened plasma cells based on central review of bone marrow samples obtained at study entry; the group 
at standard risk were patients without these genetic subtypes; patients with unknown cytogenetics had 
samples that were sent to the central laboratory for testing, but these were not analysable or did not yield 
a definitive result; patients with missing cytogenetics did not have samples that were sent to the central 
laboratory for testing. 
A subset of patients was enrolled in a preplanned substudy assessing right and left heart function. Patients 
were assessed with two-dimensional transthoracic echocardiogram at baseline, every 12 weeks, and at the 
end-of-treatment visit. Additional methods relating to the echocardiogram substudy are presented in the 
appendix (p 12). 
 
Outcomes 
The primary endpoint was progression-free survival based on the independent review committee's disease 
outcome assessments, defined as the time from randomisation until disease progression or death due to 
any cause, whichever occurred first. Secondary endpoints included overall survival (defined as the time 
from randomisation to death due to any cause), overall response (partial response or better), duration of 
response (calculated for patients who achieved a partial response or better; for such patients, duration of 
response was defined as the time from first evidence of a partial response or better to confirmation of 
disease progression or death from any cause), incidence of grade 2 or higher peripheral neuropathy events, 
and safety. A stringent complete response was defined by a negative immunofixation test for myeloma 
protein in urine and the disappearance of any soft-tissue plasmacytomas, with less than 5% of plasma cells 
in bone marrow, a normal serum free light chain ratio, and an absence of clonal cells in the bone marrow; 
definitions of complete response, very good partial response, partial response, minimal response, stable 
disease, and progressive disease are in the appendix (p 18). 
 
Statistical analysis 
Progression-free survival and overall survival were compared between treatment groups using a log-rank 
test and the corresponding hazard ratio (HR) was estimated using a Cox regression model. In total, 526 
events (disease progression or death) were needed to provide 90% power to detect a 25% reduction in the 
risk of disease progression or death (HR 0·75) at a two-sided significance level of 0·05. Based on the 
assumptions of an exponential distribution of progression-free survival, median progression-free survival of 
10·0 months in the bortezomib group and 13·3 months in the carfilzomib group, and a 3% dropout rate, a 
total of 888 patients enrolled over a 22 month period (including a 9 month enrolment ramp-up period and 
an 8 month follow-up period after planned closure of enrolment) was expected to result in the required 
526 events. 
An interim analysis was scheduled after about 395 events had occurred (75% of the required total). The 
objective of the planned interim analysis was to monitor differences between treatment groups for 
evidence of substantial benefit of carfilzomib and dexamethasone versus bortezomib and dexamethasone. 
An O'Brien-Fleming stopping boundary for efficacy was calculated with the use of a Lan-DeMets alpha-
spending function so that the overall type I error was less than or equal to 0·05 (two-sided).13 and 14 The 
stopping boundary was to be based on the actual number of events (disease progression or death) 
recorded up to the data cutoff date. An independent data and safety monitoring committee, which 
monitored overall study conduct and assessed safety and efficacy data, reviewed the study data, 
designated as arm A and arm B instead of the actual control and test treatment groups; unmasking of the 
study occurred at the interim analysis. The membership criteria and other details regarding this committee 
are presented in the appendix (p 7). 
If the data monitoring committee determined that the observed p value at the interim analysis of 
progression-free survival was less than or equal to the stopping boundary (nominal significance level), then 
the study was to be regarded as having met its primary endpoint. If the primary endpoint showed a 
significant difference between treatment groups at the interim analysis, then the secondary endpoints of 
overall survival, overall response, and the incidence of grade 2 or higher neuropathy events were to be 
tested. The multiplicity in the secondary endpoint testing was adjusted by the group sequential Holm 
procedure to ensure a strong control of the overall studywise type 1 error at 0·05.15 For the interim overall 
survival analysis, a two-sided significance level of 0·0002 was used for the prespecified monitoring 
boundary for efficacy. Duration of response was summarised descriptively using the Kaplan-Meier method. 
Efficacy assessments were based on the intention-to-treat population (consisting of all randomly assigned 
patients). The safety analysis included patients who received at least one dose of study treatment. 
The overall response was compared between groups using a Mantel-Haenszel test, and the associated odds 
ratio (OR) and 95% CI were estimated. A Pearson χ2 test was used to compare the incidence of grade 2 or 
higher peripheral neuropathy between treatment groups, and the OR and 95% CI were estimated. For the 
echocardiogram substudy, we used a mixed model for repeated measures under the assumption of 
missing-at-random to estimate longitudinal differences between the treatment groups in the reduction of 
left ventricular ejection fraction and right ventricular function. 
 
For the distribution of time-to-event endpoints, the medians and 95% CIs were estimated using the Kaplan-
Meier point estimates. For median follow-up data, the IQR was calculated. All reported p values are two-
sided. SAS software version 9.3 was used for the statistical analyses. This study is registered with 
Clinicaltrials.gov, number NCT01568866. 
 
Role of the funding source 
The trial was designed by the senior authors (MAD, PM, AP, DJ, RH, TF, HL, HG, RO, HHG, NM, SF, WJC) and 
the funder. Data were collected and analysed by the funder. The funder collaborated with the authors in 
the interpretation of the data. An initial draft of the manuscript was prepared by the funder and a 
professional medical writer paid by the funder in collaboration with the authors. All authors contributed to 
subsequent drafts, had full access to the data, made the decision to submit the manuscript for publication, 
and agreed to be accountable for the accuracy and integrity of the data and analyses. The corresponding 




Between June 20, 2012, and June 30, 2014, 929 patients from North America, Europe, South America, and 
the Asia-Pacific region were randomly assigned to treatment (464 to the carfilzomib group and 465 to the 
bortezomib group; figure 1). 360 (79%) patients in the bortezomib group received subcutaneous 
bortezomib throughout study treatment; all others received intravenous bortezomib at some point during 
treatment. Baseline characteristics were generally balanced between treatment groups (table 1; appendix p 
15). 215 (46%) of 464 patients in the carfilzomib group and 244 (52%) of 465 in the bortezomib group had a 
history of peripheral neuropathy. 
The cutoff date for the prespecified interim analysis was Nov 10, 2014. At data cutoff, 200 (43%) of 464 
patients in the carfilzomib group and 105 (23%) of 465 in the bortezomib group were still receiving 
treatment. In the intention-to-treat population, 414 events (disease progression or death), based on 
outcomes assessed by the independent review committee, had occurred (171 events in the carfilzomib 
group; 243 events in the bortezomib group). Based on this number of events, the O'Brien-Fleming stopping 
boundary for efficacy (two-sided p value) was 0·023. Median follow-up for progression-free survival was 
11·9 months (IQR 9·3–16·1) in the carfilzomib group and 11·1 months (8·2–14·3) in the bortezomib group. 
Median progression-free survival was 18·7 months (95% CI 15·6 to not estimable) in the carfilzomib group 
versus 9·4 months (8·4–10·4) in the bortezomib group (HR 0·53 [95% CI 0·44–0·65]; p<0·0001; figure 2A). In 
pre-planned exploratory subgroup analyses, the effect of carfilzomib on progression-free survival in 
patients with or without previous bortezomib treatment (figure 2B and C), and in all other subgroups was 
similar to that in the overall population (figure 3; appendix pp 13, 16–17). Because of the small number of 
patients with previous carfilzomib exposure in this study, the effect of carfilzomib on progression-free 
survival in patients with or without previous carfilzomib exposure was not analysed. 
The proportion of patients achieving an objective response was 77% (95% CI 73–81) in the carfilzomib 
group compared with 63% (58–67) in the bortezomib group (odds ratio [OR] 2·03 [95% CI 1·52–2·72]; 
p<0·0001). The best overall responses are shown in table 2. The median duration of response was 21·3 
months (95% CI 21·3 to not estimable) for the carfilzomib group and 10·4 months (95% CI 9·3–13·8) for the 
bortezomib group. Median time to response was 1·1 months (IQR 1·0–2·0) in the carfilzomib group and 1·1 
months (1·0–1·9) in the bortezomib group. 
Overall survival data were immature at the interim analysis (with 163 [33%] of 496 total deaths required for 
final analysis) and did not cross the prespecified monitoring boundary (two-sided significance level of 
0·0002). Median follow-up for overall survival was 12·5 months (IQR 9·6–16·6) in the carfilzomib group and 
11·9 months (9·3–15·9) in the bortezomib group. As of data cutoff on Nov 10, 2014, there were 75 deaths 
in the carfilzomib group and 88 deaths in the bortezomib group (HR 0·79 [95% CI 0·58–1·08]; p=0·13; 
appendix p 14). 
The median duration of treatment was 39·9 weeks (IQR 23·7–53·0) in the carfilzomib group and 26·8 weeks 
(15·0–42·0) in the bortezomib group. Median relative dose intensity of proteasome inhibitor treatment was 
93% (IQR 84–98) in the carfilzomib group and 86% (71–96) in the bortezomib group. 
The most common adverse events and adverse events of interest are shown in Table 3 and Table 4; all 
other adverse events are shown in the appendix (pp 22–28). The most common grade 3 or higher adverse 
events were anaemia (67 [14%] of 463 patients in the carfilzomib group vs 45 [10%] of 456 patients in the 
bortezomib group), hypertension (41 [9%] vs 12 [3%]), thrombocytopenia (39 [8%] vs 43 [9%]), and 
pneumonia (32 [7%] vs 36 [8%]). 
The number of patients who had grade 2 or higher peripheral neuropathy (grouped term) was significantly 
higher in the bortezomib group than in the carfilzomib group (146 [32% (95% CI 27·7–36·3)] of 456 vs 28 
[6% (3·9–8·2)] of 463 patients; OR 0·14 [95% CI 0·09–0·21] p<0·0001); this result was irrespective of 
peripheral neuropathy status at baseline ( appendix pp 23–24). Although grade 3 or higher peripheral 
neuropathy (grouped term) was more common in patients who received bortezomib intravenously 
throughout treatment than in patients who received bortezomib subcutaneously throughout treatment 
(seven [9%] of 75 vs 27 [8%] of 360 patients; 21 patients switched between subcutaneous and intravenous 
bortezomib during treatment), grade 2 or higher peripheral neuropathy (grouped term) was more common 
with subcutaneous bortezomib treatment than with intravenous bortezomib treatment (120 [33%] of 360 
patients vs 16 [21%] of 75 patients). 
Serious adverse events were reported in 224 (48%) of 463 patients in the carfilzomib group and 162 (36%) 
of 456 patients in the bortezomib group (appendix p 25). In the intention-to-treat population, 263 (57%) of 
464 patients in the carfilzomib group and 351 (75%) of 465 patients in the bortezomib group discontinued 
treatment (figure 1; appendix p 19). The most common adverse events leading to treatment 
discontinuation in the safety population are shown in the appendix (p 20). Peripheral neuropathy was the 
most common adverse event to result in treatment discontinuation in the study in the safety population, 
occurring in ten (2%) of 456 patients in the bortezomib group and in no patients in the carfilzomib group 
(appendix p 20). Dose reductions due to adverse events occurred in 106 (23%) of 463 patients in the 
carfilzomib group and in 218 (48%) of 456 patients in the bortezomib group (appendix p 21). 135 (62%) of 
218 dose reductions in the bortezomib group were due to neuropathy-related adverse events compared 
with seven (7%) of 106 in the carfilzomib group. Bortezomib dose reductions due to peripheral neuropathy 
(grouped term) occurred in 29 (31%) of 95 patients who received intravenous bortezomib at first dose and 
106 (29%) of 361 patients who received subcutaneous bortezomib at first dose (the numbers here are for 
patients who received subcutaneous bortezomib at first dose, but not necessarily throughout treatment). 
During treatment, or within 30 days of receiving the last dose of study treatment, 22 (5%) of 464 patients in 
the carfilzomib group died (six due to infection, five to cardiac events, four to disease progression, two to 
sudden deaths, one to acute myeloid leukaemia, one to hepatic failure, one to respiratory failure, one to 
spinal cord compression, and one to tumour lysis syndrome) and 21 (5%) of 465 patients in the bortezomib 
group died (eight due to infection, six to cardiac events, four to disease progression, one to head injury, one 
to lung disorder, and one unknown). 
In a preplanned substudy, serial echocardiograms from 151 patients (75 from the carfilzomib group and 76 
from the bortezomib group) identified one patient (in the bortezomib group) with significant left 
ventricular ejection fraction reduction within the first 24 weeks of study treatment. Three additional 
patients (two from the carfilzomib group and one from the bortezomib group) had a significant reduction in 
left ventricular ejection fraction at any time during the study. All patients but one (in the carfilzomib group) 
had resolution to normal left ventricular ejection fraction on follow-up. Mixed models for repeated 
measures analysis of left ventricular ejection fraction reduction and right ventricular function found that 
neither treatment effect nor the treatment-by-time interaction were significantly different between the 
treatment groups (p values ranged from 0·07 to 0·91). 
 
Discussion 
In this randomised, phase 3 study, patients treated with carfilzomib and dexamethasone had longer 
progression-free survival than those treated with bortezomib and dexamethasone. Progression-free 
survival in all subgroups, including bortezomib-naive patients and patients with high-risk or standard-risk 
cytogenetics, was longer in the carfilzomib group than in the bortezomib group. However, neither 
proteasome inhibitor appeared to significantly overcome the adverse prognostic effect of high-risk 
cytogenetics; in both treatment groups, patients with high-risk cytogenetics had shorter progression-free 
survival than the overall population. Progression-free survival was also longer for patients in the carfilzomib 
group than for those in the bortezomib group irrespective of previous transplant status; the difference 
between the treatment groups was smaller in patients with a previous transplant versus those without, 
possibly because the former is a more challenging population to treat due to transplant-related toxic 
effects. Overall survival data were immature at the time of the interim analysis. Patients will continue to be 
followed for mortality until the final overall survival analysis is done; the end of the study will be defined as 
when the final overall survival analysis takes place, or in one of the planned interim analyses. 
The proportion of patients achieving an objective response in the carfilzomib group was higher than that of 
the bortezomib group, and the carfilzomib group had a longer median duration of response. The finding 
that the proportion of patients with a complete response or better and very good partial response or better 
was higher in the carfilzomib group than in the bortezomib group is encouraging because studies have 
shown an association between depth of response and improved survival in patients with multiple 
myeloma.16 
In the bortezomib group, the median progression-free survival was consistent with historical data from 
phase 2 and 3 clinical trials17, 18 and 19 assessing bortezomib and dexamethasone in patients with 
relapsed or refractory multiple myeloma (median progression-free survival, 3·8–11·9 months). Although 
bortezomib plus dexamethasone is considered a standard of care, bortezomib-related peripheral 
neuropathy was among the most common adverse events that led to treatment discontinuation in phase 2 
and 3 studies of bortezomib.3, 6 and 7 In the present study, peripheral neuropathy was the most common 
adverse event to result in treatment discontinuation in either treatment group. 
The duration of treatment was longer in the carfilzomib group than in the bortezomib group, which might 
have contributed to a higher frequency of grade 3 or higher adverse events and serious adverse events; 
however, treatment discontinuations and treatment-related deaths due to adverse events were 
comparable between groups. A number of known adverse drug reactions were reported more frequently in 
the carfilzomib group than in the bortezomib group, including any-grade dyspnoea, hypertension, pyrexia, 
and cough (preferred terms), any-grade cardiac failure, and acute renal failure (grouped terms). A higher 
frequency of grade 3 or higher hypertension (preferred term), dyspnoea (preferred term), cardiac failure 
(grouped term), acute renal failure (grouped term), and pulmonary hypertension (grouped term) were also 
noted in the carfilzomib group compared with the bortezomib group. Hypertension, in particular, is a 
known and manageable side-effect with carfilzomib. Grade 3 or higher ischaemic heart disease (grouped 
term) was similar between the groups. 
The proportion of patients in the carfilzomib group with grade 2 or higher neuropathy was lower than that 
in the bortezomib group. In the bortezomib group, grade 2 or higher peripheral neuropathy was more 
frequent in patients who received subcutaneous administration of bortezomib compared with those who 
received intravenous administration. This finding might be because patients with a history of peripheral 
neuropathy were more likely to have received subcutaneous administration of bortezomib than 
intravenous administration. 
Importantly, a preplanned substudy using serial echocardiograms showed no evidence of cumulative 
cardiac injury or increased risk of left or right ventricular dysfunction in patients treated with carfilzomib 
compared with bortezomib, suggesting limited use for serial screening with echocardiography as a risk 
mitigation tool for unselected patients receiving carfilzomib. The factors associated with the higher risk for 
certain cardiac and pulmonary adverse events in the overall study population is unclear and probably 
multifactorial (eg, pre-existing comorbidities, disease characteristics, possible volume overload as a result 
of pre-carfilzomib and post-carfilzomib hydration, and, for hypertension, carfilzomib dose). Although cross-
trial comparisons should be viewed with caution, the frequency of any-grade cardiac failure (grouped term) 
reported in the carfilzomib group of this study with carfilzomib doses of 20 mg/m2 and 56 mg/m2 were 
consistent with frequencies reported in the ASPIRE20 study with carfilzomib doses of 20 mg/m2 and 27 
mg/m2 when given in combination with lenalidomide and dexamethasone (8·2% vs 6·4%), and in the phase 
2 studies 21 of single-agent carfilzomib at doses of 20 mg/m2 and 27 mg/m2 in patients with relapsed or 
refractory multiple myeloma or both (7·2%). 
To our knowledge, the ENDEAVOR trial is the first phase 3 head-to-head comparison between two 
proteasome inhibitors and the largest phase 3 randomised trial to date in patients with relapsed or 
refractory myeloma. Although limited by an open-label design, our study provides important information 
about the relative efficacy and safety of these two proteasome inhibitors. In this study, the longer 
progression-free survival in patients treated with carfilzomib and dexamethasone compared with 
bortezomib and dexamethasone is probably the result of several factors. By contrast with bortezomib, 
carfilzomib is an irreversible proteasome inhibitor that produces sustained proteasomal inhibition. 
Preclinically, carfilzomib is more potent than bortezomib in proteasome inhibitor-naive multiple myeloma 
cell lines and can overcome bortezomib resistance in multiple myeloma cell lines and patient samples.22 In 
preclinical models, carfilzomib had less off-target activity against serine proteases compared with 
bortezomib.23 This selectivity might have been responsible for the lower frequency of grade 2 or higher 
peripheral neuropathy in the carfilzomib group compared with the bortezomib group in this study. The 
acceptable safety and tolerability profile of carfilzomib given as a 30 min infusion, particularly with respect 
to peripheral neuropathy, might allow patients to receive carfilzomib at a higher dose than the approved 
label dose (20 mg/m2 and 56 mg/m2vs 20 mg/m2 and 27 mg/m2), with a longer treatment duration and 
fewer dose reductions compared with bortezomib at a dose of 1·3 mg/m2, as reported in this study. The 
ongoing randomised phase 2 S1304 study (NCT01903811), which is comparing carfilzomib 20 mg/m2 and 
27 mg/m2 plus dexamethasone versus carfilzomib 20 mg/m2 and 56 mg/m2 plus dexamethasone in 
patients with relapsed or refractory multiple myeloma, will provide important information about the 
relative efficacy and safety of these doses. 
Taken together, the results from the ENDEAVOR study suggest an important role for carfilzomib-based 
regimens for patients with relapsed or refractory multiple myeloma. In this patient population, one might 
consider using carfilzomib and dexamethasone in cases where bortezomib and dexamethasone would also 





Research in context 
Evidence before this study 
Bortezomib and dexamethasone is a standard treatment option worldwide for patients with multiple 
myeloma. We searched PubMed for clinical studies in multiple myeloma that have assessed carfilzomib with 
dexamethasone in patients with relapsed or refractory multiple myeloma. Specific search terms included 
“carfilzomib”, “dexamethasone”, “relapsed”, “refractory”, “second-line”, “third-line”, “salvage”, and 
“multiple myeloma”. We included all English language studies published until June 14, 2015. 
We identified two studies that assessed the combination of carfilzomib and dexamethasone in patients with 
advanced multiple myeloma. In a phase 1b/2 study, carfilzomib showed promising activity and tolerability in 
combination with dexamethasone in patients with relapsed or refractory multiple myeloma or both. In a 
phase 2 study, treatment with carfilzomib with or without dexamethasone resulted in a high overall 
response and durable disease control in heavily pretreated patients with relapsed or refractory multiple 
myeloma, but was also associated with hypertension and heart failure. These studies suggested that 
carfilzomib with dexamethasone is a promising treatment option for patients with relapsed or refractory 
multiple myeloma. 
Added value of this study 
To our knowledge, ENDEAVOR is the first phase 3 head-to-head comparison between two proteasome 
inhibitors and is the largest phase 3 randomised trial to date in patients with relapsed or refractory multiple 
myeloma. In this study, patients treated with carfilzomib and dexamethasone had longer progression-free 
survival compared with those treated with bortezomib and dexamethasone. Overall, the results from 
ENDEAVOR suggest an important role for carfilzomib-based regimens for the treatment of patients with 
relapsed or refractory multiple myeloma. 
Implications of all the available evidence 
Compared with bortezomib and dexamethasone, carfilzomib with dexamethasone was associated with a 
significant and clinically meaningful improvement in progression-free survival. Furthermore, carfilzomib 
with dexamethasone had an acceptable adverse event profile. These results delineate the favourable 
benefit–risk profile of this regimen. Carfilzomib and dexamethasone should be considered as a treatment 
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Table 4 Adverse events of interest in the safety population 
 
